Combination checkpoint inhibition of PD-1 with CTLA-4 has been evaluated in melanoma, leading to a higher rate of objective response, progression free survival (PFS) and marginally overall survival (OS) than with anti-PD-1 alone, albeit with greater levels of toxicity [21, 22]. This evidence concerns the gene CTLA4 and melanoma.